Program
MDR-001
A development code.
Its studies are mostly in Obesity · Overweight · Lymphoma, Follicular, led by MindRank AI.
Furthest: phase 3, since Nov 18, 20256 company-led studies, 5 open or runningNext primary completion: Jun 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| MindRank AI | 65 open or running | phase 3since Nov 18, 2025 | Sep 16, 2024 | Jun 2027phase 3 · NCT07274137 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 16, 2024First study: phase 2 study in ObesityFirst studyNCT06606483 · 300 planned · China
- Jan 7, 2025Phase 2 study in OverweightNCT06778850 · 128 enrolled · China
- Jul 23, 2025Phase 1 study in ObesityNCT07110766 · 24 planned · China
- Nov 18, 2025Phase 3 study in OverweightPhase 3 reachedNCT07274137 · 738 planned · China
- Apr 11, 20262 phase 1 studiesNCT07550634, NCT07550621
Ahead
- Jun 2027Primary completion: phase 3 study in OverweightNCT07274137
TargetBeta
GLP1R →read by rule
“A single oral dose of MDR-001, a GLP-1 receptor agonist, will be administered to participants with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment and to matched healthy controls.”study text, by rule · the study
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| zenagamtide | Novo Nordisk | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07550634Lymphoma, Follicular · China | 1 | Not yet recruiting | Jul 8, 2026 | 32 |
| NCT07550621Healthy Volunteers (HV) · China | 1 | Not yet recruiting | May 31, 2026 | 28 |
| NCT07274137Overweight · China | 3 | Not yet recruiting | Jun 2027 | 738 |
| NCT07110766Obesity · China | 1 | Not yet recruiting | Sep 15, 2025 | 24 |
| NCT06778850Overweight · China | 2 | Completed | Jul 15, 2024 | 128 |
| NCT06606483Obesity · China | 2 | Not yet recruiting | Jul 30, 2025 | 300 |
How it is read
Names in the registry
- “MDR-001”, 6 entries
Codes read as this program: MDR001.
Conditions, from the studies’ own filings
- Obesity, 3 studies
- Overweight, 1 study
- Lymphoma, Follicular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.